to the position of ChiefMedical Officer Dr

If he does re-structure, I want him to come into training camp at a lean n' mean 250, and take up Rich Gannon on those lessons, so he can work on his decision making and footwork. On the other hand, if he refuses to restructure; just cut our losses as 2010 will likely be an uncapped year.Coaching ChangesFirst thing first, I believe that firing Tom Cable would be a grave mistake. I do, however, think that Tom Cable should stop calling the plays and bring in an offensive cooridnator to resume the position. He has done a horrific job with the wide receivers this year. SAN MATEO, Calif.(Business Wire)Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on noveltherapies for autoimmune and chronic inflammatory diseases and pain, todayannounced the appointment of Michael M Kitt, M.D., to the position of ChiefMedical Officer "Dr.

Kitt is an experienced clinician who will lead Nuons clinical developmentprograms in the area of autoimmune disease. Michael has been responsible for thesuccessful completion of clinical trials in a variety of clinical indicationsand will be able to apply his extensive knowledge and depth of expertise to ourprograms," said Rodney Pearlman, Ph.D., President and CEO of Nuon Therapeutics."Michael has functional experience in multiple areas involved in drugdevelopment and has a keen grasp of the issues and challenges in taking a drugthrough the clinical development process. He also has considerable regulatoryexperience, which will be invaluable as we advance our lead compound, tranilast,into clinical trials." Dr. Kitt was most recently Senior Vice President, Development at Theravance,Inc., where he had responsibilities for Clinical Research, Medical Affairs,Biostatistics & Data Management, Regulatory Affairs, Preclinical, Safety &Toxicology and Project Management. He was involved in filing numerous INDs,taking one compound through to NDA stage Prior to this, Dr. Kitt was VicePresident of Clinical Research at COR Therapeutics, where he was responsible forthe clinical program for Integrilin, which was approved for two indications inboth the U.S and Europe Previously, he was Sr. Vice President for ClinicalResearch at Sterling-Winthrop, where he was involved in the clinical developmentof a number of novel compounds.

Prior to that, at the Upjohn Company, he heldnumerous positions in the clinical field, including several years in theEuropean Clinical Research Office in Belgium Dr Kitt has a B.S. in Chemistryfrom the Polytechnic University in New York and an M.D from NYU About Nuon Therapeutics, Inc.Nuon Therapeutics, Inc. Nuon Therapeutics initial programs, based on an exclusivelicense to technology developed by Imperial College London and StanfordUniversity, are focused on developing tranilast to treat rheumatoid arthritis,multiple sclerosis and pain. New Camcorders Offer Advanced Technology for Higher Image Quality and EasyOperation Across a Variety of Recording FormatsLAKE SUCCESS, N.Y.(Business Wire)Canon U.S.A., Inc, a leader in digital imaging technology, announces an excitingnew line of five VIXIA high definition and six standard definition camcorders,which are available in a variety of different recording formats, including FlashMemory. The camcorders retain Canons core imaging technologies, but add a wideselection of new features for enhanced image quality and added flexibility forsharing and storing memories. Highlighting the list of new features is Canons newest and most sophisticatedimage processor, DIGIC DV III. Also new to Canons video line-up is Video Snapshot Mode, which enables users tocapture the highlights of a once in a lifetime trip, or a family milestone, withthe same ease as taking photos.